Post-Approval Safety Study (PASS) of Lenalidomide Compared with Other Treatments In Patients with Relapsed or Refractory Multiple Myeloma: Evaluation of Peripheral Neuropathy In the First 1,011 Patients
Michel Delforge(KU Leuven), Renato Zambello(University of Padua), Barbara Rosettani(National and Kapodistrian University of Athens), Javier de la Rubia(Universitat de València), Igor Wolfgang Blau(Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie), Miguel‐Teodoro Hernández(Hospital Universitario de Canarias), Nancy A. Brandenburg(Unknown), Janine Collins(NHS Blood and Transplant), Roman Hájek(University Hospital Ostrava), Henk M. Lokhorst(Amsterdam UMC Location Vrije Universiteit Amsterdam), Laurence Sanhès(Centre Hospitalier de Perpignan), Giacinto La Verde(Azienda Ospedaliera Sant'Andrea), Luciano Masini(Casa di Cura Villa Garda)
Cited by 1
Related Papers
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
|Leukemia|2008|808
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695